<DOC>
	<DOCNO>NCT02630927</DOCNO>
	<brief_summary>The purpose study investigate drug call AG-519 , develop treatment disease call pyruvate kinase deficiency ( also know PK deficiency ) form anemia . This study 5 part study Part 1 enrol healthy volunteer single ascend dose ( SAD ) group , Part 2 enrol healthy volunteer multiple ascend dose ( MAD ) group Part 3 enrol healthy volunteer investigate much study drug take body food affect uptake prototype formulation AG-519 , Part 4 enrol healthy volunteer Japanese origin compare result subject non-Japanese origin , Part 5 non-randomized , open-label , multiple dose study enrol healthy volunteer investigate much study drug take body dose 14 day .</brief_summary>
	<brief_title>A Safety Tolerability Study AG-519 Healthy Subjects</brief_title>
	<detailed_description />
	<criteria>1 . Healthy adult male female subject . Female subject must nonchildbearing potential . 2 . Age 18 60 year inclusive time consent . 3 . Body mass index ( BMI ) ≥18.5 ≤32.0 kg/m2 , outside range , consider clinically significant investigator . 4 . Good state health ( mentally physically ) indicate comprehensive clinical assessment ( detailed medical history complete physical examination ) , ECG laboratory investigation . 5 . Subjects actively nonsmoker use nicotinecontaining product least 12 month prior screen assessment . 6 . Must willing able communicate participate whole study . 7 . Must provide write informed consent . 8 . Must agree use adequate method contraception . 9 . Japanese subject enrol Part 4 must first generation : bear Japan , live outside Japan 5 10 year , able trace maternal paternal Japanese ancestry , significant change lifestyle , include diet ( least one Japanese meal consume per day ) , since leave Japan . 1 . Participation clinical research study within previous 3 month . 2 . Subjects study site employee , immediate family member study site sponsor employee . 3 . Subjects previously enrol study . 4 . History drug alcohol abuse past 2 year . 5 . Regular alcohol consumption male &gt; 21 unit per week female &gt; 14 unit per week ( 1 unit = ½ pint beer , 25 mL 40 % spirit 125 mL glass wine ) . 6 . Current smoker smoke within last 12 month . A breath carbon monoxide read great 10 ppm screening . 7 . Any female childbearing potential . 8 . Subjects suitable vein multiple venepunctures/cannulation assess investigator screening . 9 . Subjects , 10 min supine rest , systolic blood pressure ( BP ) ≥140 mmHg ( ≥150 mmHg subject &gt; 45 year age ) diastolic BP ≥90 mmHg . 10 . Male subject QTcF interval ( Fridericia 's correction factor ) ECG &gt; 450 msec , female subject QTcF interval ECG &gt; 470 msec screen Day 1 ( pre dose ) ECG . 11 . Subjects history serious mental illness , include , limited schizophrenia , bipolar disorder , major depression . 12 . Subjects glucose6phosphatedehydrogenase ( G6PD ) deficiency . 13 . Subjects history primary malignancy , include history melanoma suspicious undiagnosed skin lesion . 14 . Subjects medical psychological condition , deem investigator likely interfere subject 's ability sign inform consent , cooperate , participate study . 15 . Subjects undergone major surgery within 6 month prior screen . 16 . Clinically significant abnormal biochemistry , hematology urinalysis judge investigator . 17 . Positive drug abuse test result screen admission . 18 . Positive hepatitis B surface antigen ( HBsAg ) , hepatitis C virus antibody ( HCV Ab ) human immunodeficiency virus ( HIV ) result . 19 . Subjects take , take , prescribed overthecounter drug . 20 . Subjects used St. John 's Wort within 28 day first dose study drug . 21 . History cardiovascular , renal , hepatic , chronic respiratory GI disease , hematologic , lymphatic , neurolologic , endocrine , psychiatric , musculoskeletal , genitourinary , immunologic , dermatologic connective tissue disease disorder , judge investigator . 22 . Serious adverse reaction serious hypersensitivity drug formulation excipients , include history allergy sulfonamide . 23 . Presence history clinically significant allergy require treatment , judge investigator . 24 . Donation loss great 400 mL blood within previous 3 month . 25 . Failure satisfy investigator fitness participate reason .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Safety Tolerability</keyword>
	<keyword>Pharmacokinetic Study</keyword>
	<keyword>Healthy Volunteer</keyword>
	<keyword>Pyruvate Kinase</keyword>
	<keyword>Rare Genetic</keyword>
</DOC>